Metagenomi Therapeutics reported cash from operations of -$19.51M and free cash flow of -$19.54M for the quarter ended Jun 2026, up 8.2% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Net Income | -11.74M | -13.01M | -19.82M | -19.29M | -25.15M | -10.74M | -18.77M | -23.40M | -25.04M | -19.91M | -20.39M | -4.12M | -23.06M | -27.48M |
| Share-based Compensation | 30.61M | 0.66M | 3.27M | 0.23M | 5.06M | 4.51M | 3.22M | 3.41M | 2.93M | 3.22M | 3.01M | 2.69M | 2.55M | 2.27M |
| Asset Writedowns and Impairment | 0.01M | 0.00M | 0.28M | 0.01M | 0.75M | 0.18M | ||||||||
| Cash from Operations | -21.00M | -26.09M | -23.73M | -20.59M | -29.85M | -26.31M | -26.64M | -26.28M | -22.84M | -21.25M | -21.25M | -23.55M | -21.18M | -19.51M |
| Depreciation, Depletion & Amortization | ||||||||||||||
| Amortizatization of Intangibles | 2.15M | 2.38M | 2.32M | 1.62M | 1.22M | 1.98M | 1.63M | 1.34M | 1.01M | 0.82M | 0.70M | 0.47M | 0.36M | 0.20M |
| Change in Working Capital | ||||||||||||||
| Change in Receivables | 1.60M | -1.47M | -0.37M | -0.43M | -1.06M | 0.67M | -0.24M | -0.14M | 0.09M | -0.66M | -0.30M | |||
| Change in Account Payables | 1.21M | -0.32M | 1.56M | -2.52M | 3.16M | -1.43M | -0.27M | -2.57M | 2.21M | 0.07M | -1.58M | 0.35M | 0.80M | 0.32M |
| Change in Accured Expenses | -1.30M | 1.38M | 0.66M | 0.90M | -2.96M | 3.30M | -0.92M | -0.32M | -2.65M | 0.17M | 4.02M | -3.19M | -2.03M | 2.92M |
| Change in Taxes | 1.94M | -0.76M | -0.55M | 1.10M | ||||||||||
| Other Working Capital Changes | -0.47M | -0.25M | 3.14M | 1.63M | 0.94M | -2.21M | -0.89M | -1.23M | -3.05M | -7.37M | 6.27M | -1.47M | -1.47M | -1.47M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | 2.67M | 3.15M | 2.26M | 1.74M | 0.92M | 0.67M | 1.20M | 0.33M | 0.29M | 0.13M | 0.07M | 0.09M | 0.12M | 0.03M |
| Change in Acquisitions & Divestments | 49.80M | 34.21M | 78.15M | 101.49M | 80.85M | 62.13M | 37.18M | 41.22M | 47.30M | 37.67M | 33.50M | 52.00M | 40.76M | 37.20M |
| Cash from Investing Activities | -72.07M | -18.72M | 75.89M | 60.63M | -94.73M | -13.04M | -8.93M | 28.55M | 24.73M | 19.07M | 27.36M | 32.37M | 3.99M | 33.17M |
| Financing Activities | ||||||||||||||
| Other financing activities | 86.54M | -2.03M | -0.49M | 0.08M | 0.28M | 0.19M | 0.02M | 0.03M | 0.01M | |||||
| Change in Capital Stock | ||||||||||||||
| Net Shares Issued and Repurchased | 0.06M | 0.08M | 0.11M | 0.09M | 692.00 | |||||||||
| Net Equity Issued and Repurchased | 4.29M | |||||||||||||
| Misc. | ||||||||||||||
| Cash from Financing Activities | 4.29M | -0.04M | -1.91M | -1.33M | 86.54M | -2.03M | -0.49M | -0.08M | -0.17M | -0.19M | 0.07M | -0.03M | 0.07M | |
| Change in Cash | -88.77M | -44.85M | 50.25M | 38.71M | -38.05M | -41.38M | -36.06M | 2.27M | 1.81M | -2.35M | 5.92M | 8.89M | -17.22M | 13.72M |
| Free Cash Flow | -23.66M | -29.24M | -25.99M | -22.33M | -30.77M | -26.97M | -27.84M | -26.61M | -23.13M | -21.38M | -21.33M | -23.63M | -21.30M | -19.54M |
| Net Cash Flow | -88.77M | -44.85M | 50.25M | 38.71M | -38.05M | -41.38M | -36.06M | 2.27M | 1.81M | -2.35M | 5.92M | 8.89M | -17.22M | 13.72M |